首页> 外文期刊>BMC Gastroenterology >Screening for adrenal suppression in children with inflammatory bowel disease discontinuing glucocorticoid therapy
【24h】

Screening for adrenal suppression in children with inflammatory bowel disease discontinuing glucocorticoid therapy

机译:终止糖皮质激素治疗的炎性肠病患儿肾上腺抑制作用的筛查

获取原文
           

摘要

Background Pharmacological doses of corticoids may result in adrenal suppression but with individual sensitivity. In paediatric inflammatory bowel disease (IBD), glucocorticoids are needed in the majority of the patients but there are less studies related to tapering off the drugs. The objective of this study was to estimate the frequency of adrenal insufficiency in children with IBD that were at the end of their systemic glucocorticoid therapy course. Methods The study was a retrospective case series of 59 consecutive paediatric IBD patients (median age 14.1?years; Crohn’s disease n?=?22, ulcerative colitis n?=?26, unclassified colitis n?=?11) that were on oral prednisolone therapy about to be discontinued. The study patients were treated in a tertiary university hospital setting. Serum morning cortisol was measured with Immulite 2000 cortisol kit. Values??69?nmol/l are considered to represent normal basal secretion. Results The morning cortisol was below the reference range in 20% of the patients and undetectable in 10%. Low cortisol levels associated with higher daily glucocorticoid doses (median 7.2?mg/m2 vs. 3.0?mg/m2 in patients with normal cortisol levels, p? Conclusions In paediatric IBD prolonged courses of glucocorticoids are frequent due to the steroid-dependent nature of the disease in a considerable proportion of patients. Adrenal suppression may occur in at least one fifth of the patients despite slowly tapering off the glucocorticoids. Notably, this is based on a set of serum cortisol measurements by request of experienced clinicians. All paediatric IBD patients receiving conventional doses of oral glucocorticoids should be subjected to screening for adrenal suppression when anticipated discontinuation of the drug.
机译:背景皮质类固醇的药理剂量可能导致肾上腺抑制,但具有个体敏感性。在小儿炎症性肠病(IBD)中,大多数患者都需要糖皮质激素,但与逐渐减少药物相关的研究较少。这项研究的目的是评估全身性糖皮质激素治疗疗程结束时IBD患儿肾上腺功能不全的频率。方法该研究是回顾性病例系列,对59例接受口服泼尼松龙治疗的连续小儿IBD患者(中位年龄14.1岁;克罗恩病n≥22,溃疡性结肠炎n≥26,未分类结肠炎n≥11)进行了回顾性研究。治疗即将停止。研究的患者在大学医院接受治疗。血清早晨皮质醇用Immulite 2000皮质醇试剂盒测量。 Δε69Δnmol/ l被认为代表正常的基础分泌。结果20%的患者的早晨皮质醇低于参考范围,而10%的患者未检测到。在皮质醇水平正常的患者中,低皮质醇水平与较高的每日糖皮质激素剂量相关(中位数为7.2?mg / m 2 与3.0?mg / m 2 ),p?小儿IBD糖皮质激素的病程延长是由于该病患者中相当一部分患者的类固醇依赖性疾病而引起的,尽管逐渐减少了糖皮质激素的作用,但至少有五分之一的患者可能会出现肾上腺抑制作用。应有经验的临床医生的要求进行一系列血清皮质醇测定,所有预期常规停用口服糖皮质激素的小儿IBD患者均应筛选筛查肾上腺抑制因子,以防可能停药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号